Trial Profile
A study to evaluate the corelation of vitreomacular attachment on outcomes after the administration of intravitreal aflibercept for the treatment of neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 31 May 2016 New trial record